News
VBIO
2.260
+2.73%
0.060
Weekly Report: what happened at VBIO last week (0831-0904)?
Weekly Report · 5d ago
Valion Bio appoints CFO Lisa Wolf as president, COO
TipRanks · 09/01 12:20
Valion Bio Appoints Lisa Wolf To Expanded Roles Of President, COO, Effective Immediately
Benzinga · 09/01 12:09
Valion Bio raises capital via new preferred financing
TipRanks · 09/01 10:29
Weekly Report: what happened at VBIO last week (0824-0828)?
Weekly Report · 08/31 09:35
Valion Bio Inc trading halted, news pending
TipRanks · 08/28 23:50
Valion Bio Enacts Reverse Stock Split to Maintain Listing
TipRanks · 08/27 13:00
Valion Bio Announces Reverse Stock Split
Barchart · 08/27 07:30
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Benzinga · 08/25 12:06
Why Cadeler Are Trading Higher By 6%; Here Are 20 Stocks Moving Premarket
Benzinga · 08/25 09:25
12 Health Care Stocks Moving In Monday's After-Market Session
Benzinga · 08/24 21:06
Weekly Report: what happened at VBIO last week (0817-0821)?
Weekly Report · 08/24 09:35
12 Health Care Stocks Moving In Wednesday's Intraday Session
Benzinga · 08/19 17:05
12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga · 08/18 17:05
Valion Bio Secures New Series B Preferred Financing
TipRanks · 08/17 10:29
Weekly Report: what happened at VBIO last week (0810-0814)?
Weekly Report · 08/17 09:35
Valion Bio says Ukraine Ministry of Health accepts entolimod regulatory dossier
TipRanks · 08/17 07:28
12 Health Care Stocks Moving In Thursday's Intraday Session
Benzinga · 08/13 17:05
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Benzinga · 08/13 12:05
Why Omeros Shares Are Trading Higher By Over 17%; Here Are 20 Stocks Moving Premarket
Benzinga · 08/13 09:16
More
Webull provides a variety of real-time VBIO stock news. You can receive the latest news about Valion Bio Inc through multiple platforms. This information may help you make smarter investment decisions.
About VBIO
Valion Bio, Inc., formerly Tivic Health Systems, Inc., is a late-stage immunotherapeutics company. The Company offers Entolimod, which is a drug used to treat acute radiation syndrome (ARS). Entolimod is a toll-like receptor 5 (TLR5) agonist that activates an innate immune pathway to prevent cell death in the bone marrow and epithelial tissues across systems impacted by radiation and age. Its pipeline also includes Entolimod to treat neutropenia and lymphocyte exhaustion, as well as Entolasta, an immunologically optimized variant of Entolimod for chronic applications. Its subsidiary, Velocity Bioworks, is a full-service contract development and manufacturing organization (CDMO) that is based in San Antonio, Texas. It offers upstream and downstream process development and optimization; analytical testing, assay development, and qualification; quality control and stability testing; microbial and mammalian expression systems; technology transfer and program management services.